Spironolactone to treat hypertension in end-stage renal disease : analysis of effectiveness and safety
Purpose: Cardiovascular events and complications are the major causes of death in patients with end-stage renal disease (ESRD)¹⁻³. Antihypertensive agents that block the renin-angiotensin-aldosterone system (RAAS) are considered first-line therapy in patients with ESRD as these patients have a prope...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | en_US |
| Published: |
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/2152/22994 |